<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852354</url>
  </required_header>
  <id_info>
    <org_study_id>20-01021289</org_study_id>
    <nct_id>NCT04852354</nct_id>
  </id_info>
  <brief_title>Tissue Collection for Drug Screening and Bioanalysis</brief_title>
  <official_title>Tissue Collection for Drug Screening and Bioanalysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to improve upon the knowledge currently available about&#xD;
      pediatric central nervous system (CNS) tumors by further examining tissue, blood, and saliva&#xD;
      samples from consenting patients. Parents of patients with CNS tumor may also be asked to&#xD;
      provide saliva samples for analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this project is to enable the acquisition of tissue available for research with&#xD;
      the prospect of enabling the development of new therapeutic avenues for patients diagnosed&#xD;
      with cancer in the central nervous system.&#xD;
&#xD;
      During the patient's routine operative procedure, if extra tissue deemed unnecessary for&#xD;
      diagnostic or clinical purposes is available, selected samples will undergo DNA and/or RNA&#xD;
      extraction and integrity analysis, whole genome and RNA sequencing, DNA and RNA methylome&#xD;
      analyses, proteomic analysis, immunoprofiling, and primary culturing of the tumor cells.&#xD;
      These cultures will then be used for drug screenings and to create patient-derived&#xD;
      xenografts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2020</start_date>
  <completion_date type="Anticipated">July 22, 2029</completion_date>
  <primary_completion_date type="Anticipated">July 22, 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating and characterizing the genetic, immunohistochemical, cellular, and molecular profiles of pediatric neoplastic lesions</measure>
    <time_frame>Through study completion, average 1-3 years</time_frame>
    <description>To develop patient-derived tissue cell lines and xenografts</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pediatric Central Nervous System Tumor</condition>
  <condition>Central Nervous System Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric and adult patients with a central nervous system tumors. Parents of patients with&#xD;
        CNS tumors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspected neoplastic central nervous system (CNS) lesions&#xD;
&#xD;
          -  Undergoing a neurosurgical procedure to remove CNS tissue and/or tumors associated&#xD;
             with this tissue&#xD;
&#xD;
          -  Tissue available in excess of that required for diagnostic or clinical purposes&#xD;
&#xD;
        May also include:&#xD;
&#xD;
          -  Parent of patient with CNS lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Greenfield, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Greenfield, M.D.</last_name>
    <phone>212-746-2363</phone>
    <email>jpgreenf@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Greenfield, M.D.</last_name>
      <phone>212-746-2363</phone>
      <email>jpgreenf@med.cornell.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rajappa P, Cobb WS, Vartanian E, Huang Y, Daly L, Hoffman C, Zhang J, Shen B, Yanowitch R, Garg K, Cisse B, Haddock S, Huse J, Pisapia DJ, Chan TA, Lyden DC, Bromberg JF, Greenfield JP. Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. Clin Cancer Res. 2017 Jun 15;23(12):3109-3119. doi: 10.1158/1078-0432.CCR-16-1508. Epub 2016 Dec 30.</citation>
    <PMID>28039266</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 10, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

